WorldCat Identities

Reynes, Jacques

Overview
Works: 23 works in 24 publications in 2 languages and 31 library holdings
Roles: Thesis advisor, Other, Contributor, Author
Publication Timeline
.
Most widely held works by Jacques Reynes
Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients by Gaël Petitjean( )

1 edition published in 2007 in English and held by 2 WorldCat member libraries worldwide

Suppression of HIV-1 replication by microRNA effectors by Christine Chable-Bessia( )

1 edition published in 2009 in English and held by 2 WorldCat member libraries worldwide

Concomitant reversible cerebral vasoconstriction syndrome and transient global amnesia by Rosalie Boitet( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status by David Morquin( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination by Dat'AIDS Study Group( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

INFECTIONS ET ADENOPATHIES CHEZ L'HEROINOMANE : ASPECTS CLINIQUES ET IMMUNOLOGIQUES: A PROPOS DE 75 OBSERVATIONS DONT 61 COMPORTANT LA SEROLOGIE LAV/HTLV III by Jacques Reynes( Book )

1 edition published in 1985 in French and held by 2 WorldCat member libraries worldwide

Osteomyelitis of the jaw: time to rethink the bone sampling strategy? by Kevin Bertrand( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Thrombosis and antiphospholipid antibody syndrome during acute Q fever( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract : Abstract: Q fever is a neglected and potentially fatal disease. During acute Q fever, antiphospholipid antibodies are very prevalent and have been associated with fever, thrombocytopenia, acquired heart valve disease, and progression to chronic endocarditis. However, thrombosis, the main clinical criterion of the 2006 updated classification of the antiphospholipid syndrome, has not been assessed in this context. To test whether thrombosis is associated with antiphospholipid antibodies and whether the criteria for antiphospholipid syndrome can be met in patients with acute Q fever, we conducted a cross-sectional study at the French National Referral Center for Q fever. Patients included were diagnosed with acute Q fever in our Center between January 2007 and December 2015. Each patient's history and clinical characteristics were recorded with a standardized questionnaire. Predictive factors associated with thrombosis were assessed using a rare events logistic regression model. IgG anticardiolipin antibodies (IgG aCL) assessed by an enzyme-linked immunosorbent assay were tested on the Q fever diagnostic serum. A dose-dependent relationship between IgG aCL levels and thrombosis was tested using a receiver operating characteristic (ROC) analysis. Of the 664 patients identified for inclusion in the study, 313 (47.1%) had positive IgG aCL and 13 (1.9%) were diagnosed with thrombosis. Three patients fulfilled the antiphospholipid syndrome criteria. After multiple adjustments, only positive IgG aCL (relative risk, 14.46 [1.85-113.14], P = .011) were independently associated with thrombosis. ROC analysis identified a dose-dependent relationship between IgG aCL levels and occurrence of thrombosis (area under curve, 0.83, 95%CI [0.73-0.93], P <.001). During acute Q fever, antiphospholipid antibodies are associated with thrombosis, thrombocytopenia, and acquired valvular heart disease. Antiphospholipid antibodies should be systematically assessed in acute Q fever patients. Hydroxychloroquine, which has been previously shown to antagonize IgG aCL pathogenic properties, should be tested in acute Q fever patients with anticardiolipin antibodies to prevent antiphospholipid-associated complications. Key Point: In addition to fever, thrombocytopenia and acquired valvular heart disease, antiphospholipid antibodies are associated with thrombosis during acute Q fever. Abstract : Supplemental Digital Content is available in the text
Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate e"0 ml/min/1.73 m2( Book )

1 edition published in 2012 in English and held by 1 WorldCat member library worldwide

Evaluation de l'activité de conseil en stratégies anti-infectieuses, intégrée au dossier médical informatisé du patient, au sein du Centre Hospitalier Régional Universitaire de Montpellier, sur la période 2013-2014 by Yatrika Asvin Koumar( Book )

1 edition published in 2014 in French and held by 1 WorldCat member library worldwide

Objectif: la stratégie institutionnelle de contrôle de l' antibiothérapie est un des piliers de la lutte contre l'émergence de la résistance bactérienne et comporte la possibilité pour les prescripteurs, de faire appel à des référents en stratégie anti-infectieuse. L'objectif principal de l'étude est d'évaluer cette activité à l'heure du dossier médical informatisé, au CHRU de Montpellier. Les objectifs secondaires sont d'identifier les perspectives et les limites du système mis en place et d'évaluer la perception du service médical rendu pour les départements demandeurs. Matériels et méthodes : une étude observationnelle de cohorte menée au centre hospitalo-universitaire régional de Montpellier a permis de colliger tous les avis donnés par l'unité mobile d' infectiologie clinique (UMIC), notifiés dans le dossier médical informatisé grâce une observat ion électronique spécifique, à l'exception de l'hospitalisation à domicile et des consultations sur la période de février 201 3 à février 2014. Résultats : 1386 télé-évaluations ont été notifiées par 6 médecins spécialistes (63% d'évaluations initiales, 25% de réévaluations et 12% de réunions de concertations), et 87 % des avis étaient donnés sans évaluation clinique au lit du malade. L'orthopédie, l'ORL, la médecine interne, l'endocrinologie, la neurochirurgie et la cardiologie étaient les services les plus demandeurs d'avis UMIC. Les avis demandés concernaient pour 27% des cas des infections ostéoarticulaires et dans 12% des cas une infection du site opératoire. Les autres motifs de demandes étaient divers. La demande était dans 65% des cas d'une évaluation de la stratégie en place, seulement 12% des avis étaient à visée diagnostique. Le nombre d'appel et le nombre d'avis par mois étaient toujours en augmentation sur les 12 mois de l'étude, bien que celle-ci ait débuté 6 mois après la mise en place de ce système. Le taux d'adhésion pour une problématique définie (n=970) était de 87% pour l'avis thérapeutique, et de 79% pour l'avis diagnostique. Entre 3 et 5 jours après l'avis de l'UMIC l'évolution de la CRP, des globules blancs et de la température étaient favorables à la moyenne dans 40% des cas. L'adhésion à l'avis de l'UMIC était associée à une diminution significative du taux de polynucléaires à J3 (p=0.003). La notification de l'avis dans courrier de sortie du patient était présente dans 43% des cas. Une réunion de concertation pluridisciplinaire était proposée par le médecin de l'UMIC dans 25% des cas, témoignant d'un fort besoin de collégialité. L'exploitation en temps réel des données saisies grâce à un système de pilotage original a permis au département des maladies infectieuses de cibler leurs formation d'augmenter la collaboration en temps réel avec les départements d' hygiène, la pharmacie et le laboratoire. Les médecins coordonnateurs des départements demandeurs d'avis ont exprimé leur satisfaction du système actuellement en place et encouragé son développement. Conclusion: L'activité de conseil en stratégies anti-infectieuses est dense, hétérogène et répond à un réel besoin croissant au sein du CHRU de Montpellier. L'adhésion est forte et améliore l'évolution précoce du patient. La mise à disposition de l'avis dé taillé dans le dossier informatisé en temps réel améliore la collaboration entre les différents acteurs de la prise en charge du patient
Le paludisme d'importation : à propos de 113 cas colligés au CHU de Montpellier by Valentine Le Barbier( Book )

1 edition published in 2004 in French and held by 1 WorldCat member library worldwide

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Background: Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dose combinations are preferred to facilitate adherence. We report 48-week results from a study comparing initial HIV-1 treatment with bictegravir--a novel INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug interactions--coformulated with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose combination to dolutegravir administered with coformulated emtricitabine and tenofovir alafenamide. Methods: In this randomised, double-blind, multicentre, placebo-controlled, non-inferiority trial, HIV-infected adults were screened and enrolled at 126 outpatient centres in 10 countries in Australia, Europe, Latin America, and North America. Participants were previously untreated adults (HIV-1 RNA ≥500 copies per mL) with estimated glomerular filtration rate of at least 30 mL/min. Chronic hepatitis B virus or hepatitis C co-infection was allowed. We randomly assigned participants (1:1) to receive oral fixed-dose combination bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or dolutegravir 50 mg with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg, with matching placebo, once a day for 144 weeks. Investigators, participants, study staff, and those assessing outcomes were masked to treatment group. All participants who received at least one dose of study drug were included in primary efficacy and safety analyses. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of less than 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm), with a prespecified non-inferiority margin of −12%. This study is registered withClinicalTrials.gov, numberNCT02607956 . Findings: Between Nov 11, 2015, and July 15, 2016, 742 participants were screened for eligibility, of whom 657 were randomly assigned to treatment (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravir group] and 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir group]). 320 participants who received the bictegravir regimen and 325 participants who received the dolutegravir regimen were included in the primary efficacy analyses. At week 48, HIV-1 RNA <50 copies per mL was achieved in 286 (89%) of 320 participants in the bictegravir group and 302 (93%) of 325 in the dolutegravir group (difference −3·5%, 95·002% CI −7·9 to 1·0, p=0·12), showing non-inferiority of the bictegravir regimen to the dolutegravir regimen. No treatment-emergent resistance to any study drug was observed. Incidence and severity of adverse events were similar between groups, and few participants discontinued treatment due to adverse events (5 [2%] of 320 in the bictegravir group and 1 [<1%] 325 in the dolutegravir group). Study drug-related adverse events were less common in the bictegravir group than in the dolutegravir group (57 [18%] of 320 vs 83 [26%] of 325, p=0·022). Interpretation: At 48 weeks, virological suppression with the bictegravir regimen was achieved and was non-inferior to the dolutegravir regimen in previously untreated adults. There was no emergent resistance to either regimen. The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated compared with the dolutegravir regimen. Funding: Gilead Sciences Inc
Anomalies métaboliques du patient infecté par le Virus de l'immunodéficience humaine (VIH) sous multithérapie antirétrovirale : vers une individualisation de la prise en charge par l'entraînement aérobie by Gilles Thöni( Book )

in French and held by 1 WorldCat member library worldwide

PARALLELEMENT A L'INTRODUCTION DES NOUVELLES MOLECULES ANTIRETROVIRALES, BEAUCOUP DE PATIENTS INFECTES PAR LE VIH ONT VU SE DEVELOPPER DES ANOMALIES DE LA REPARTITION DES GRAISSES, DES DYSLIPIDEMIES, ET/OU DES ANOMALIES DU METABOLISME OXYDATIF. NOTRE TRAVAIL S'INTERESSE AUX PROCEDURES D'ENTRAINEMENT PHYSIQUE A PRECONISER DANS LA PRISE EN CHARGE DE CES DESORDRES. UNE ANALYSE DES DESORDRES METABOLIQUES AU REPOS ET DE LA TOLERANCE A L'EXERCICE AIGU NOUS A INCITE A PROPOSER UN ENTRAINEMENT PROLONGE AU SEUIL VENTILATOIRE. CE TYPE D'ENTRAINEMENT FAVORISE UNE REDUCTION DE LA MASSE GRASSE VISCERALE ET UNE AMELIORATION DES PARAMETRES BIOLOGIQUES EN FAVEUR D'UNE REDUCTION DU RISQUE CARDIO-VASCULAIRE. L'EFFICACITE DE L'ENTRAINEMENT A ETE EVALUEE SELON L'AGE DES PATIENTS. SUR LE PLAN DE L'ACCUMULATION ADIPEUSE ET DES ANOMALIES LIPIDIQUES, L'ENTRAINEMENT EST BENEFIQUE A TOUS LES PATIENTS MAIS PLUS SPECIALEMENT AUX PATIENTS LES PLUS AGES. LES ALTERATIONS DES REPONSES DU METABOLISME OXYDATIF A L'ENTRAINEMENT DANS CE GROUPE SUGGERENT LE DEVELOPPEMENT D'UNE DYSFONCTION MITOCHONDRIALE AVEC LE VIEILLISSEMENT, MAIS LES BENEFICES SUR LE RISQUE CARDIO-VASCULAIRE RESTENT ENTIERS. NOS TRAVAUX DEMONTRENT DONC L'INTERET DE L'EXERCICE PHYSIQUE DANS LA PRISE EN CHARGE DES ANOMALIES METABOLIQUES ASSOCIES AUX THERAPIES ANTIRETROVIRALES
Diagnostic précoce de la toxoplasmose cérébrale chez le sujet séropositif VIH : intérêt d'une nouvelle méthode immunologique by Vincent Baillat( Book )

1 edition published in 1997 in French and held by 1 WorldCat member library worldwide

Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Les infections disséminées à amibes libres chez les sujets infectés par le VIH : à propos d'une observation by Thierry Casper( Book )

1 edition published in 1997 in French and held by 1 WorldCat member library worldwide

Chest Low-Dose Computed Tomography for Early Lung Cancer Diagnosis as an Opportunity to Diagnose Vertebral Fractures in HIV-Infected Smokers, an ANRS EP48 HIV CHEST Substudy( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract : Background: To estimate the prevalence of vertebral fractures on chest low-dose computed tomography (LDCT) in HIV-infected smokers. Methods: Cross-sectional study of vertebral fractures visualized on chest LDCT from a multicenter prospective cohort evaluating feasibility of chest LDCT for early lung cancer diagnosis in HIV-infected subjects. Subjects were included if 40 years or older, had been active smokers within the last 3 years of at least 20 pack-years, and had a CD4 T-lymphocyte nadir cell count <350 per microliter and an actual CD4 T-cell count>100 cells per microliter. Spinal reconstructed sagittal planes obtained from chest axial native acquisitions were blindly read by a musculoskeletal imaging specialist. Assessment of the fractured vertebra used Genant semiquantitative method. The study end point was the prevalence of at least 1 vertebral fracture. Results: Three hundred ninety-seven subjects were included. Median age was 49.5 years, median smoking history was 30 pack-years, median last CD4 count was 584 cells per microliter, and median CD4 nadir count was 168 cells per microliter; 90% of subjects had a viral load below 50 copies per milliliter. At least 1 fracture was visible in 46 (11.6%) subjects. In multivariate analysis, smoking e"0 packs-years [OR = 2.5; 95% CI: (1.2 to 5.0)] was associated with an increased risk of vertebral fracture, while HIV viral load <200 copies per milliliter [OR = 0.3; 95% CI: (0.1 to 0.9)] was protective. Conclusions: Prevalence of vertebral fractures on chest LDCT was 11.6% in this high-risk population. Smoking cessation and early introduction of antiretroviral therapy for prevention of vertebral fractures could be beneficial. Chest LDCT is an opportunity to diagnose vertebral fractures
Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

ABSTRACT : N/A: A shift in mortality and morbidity has been observed in people living with human immunodeficiency virus (PLWHIV) from acquired immunodeficiency syndrome (AIDS) to non-AIDS diseases. Lung cancer has the highest incidence rates among all the non-AIDS-defining malignancies and is associated with mortality rates that exceed those of other cancers. Strategies to increase lung cancer survival in PLWHIV are needed. Lung cancer screening with chest LDCT has been shown to be efficient in the general population at risk. The objective of this review is to discuss lung cancer screening with chest computed tomography in PLWHIV. Lung cancer screening in PLWHIV is feasible. Whether PLWHIV could benefit from an age threshold for screening that is earlier than the minimum age of 55 years usually required in the general population still needs further investigation. Studies evaluating smoking cessation programs and how they could be articulated with lung cancer screening programs are also needed in PLWHIV
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Suppressio ... to 0.99 for Tubular an ...)

Languages
English (13)

French (8)